

MOPEAD Project Press Release

22 December 2019

PRESS RELEASE

Brussels, 22 December 2019: MOPEAD presents three new publications

Gender Policy Brief: one of the project deliverables was a Gender Policy Brief. The information presented in this document is based on the most recent available data, evidence and best practice, including results from the MOPEAD project.

The Policy Brief recognises the impact of Alzheimer's disease (AD) on women as patients, carers and their families. It explores both the biological and social factors with regards to gender that impacts the development, diagnosis, progression, treatment of AD. It shows the sex and gender breakdown in the four patient engagement strategies tested and evaluated by MOPEAD using a sex and gender lens.

Sex and gender integration in AD prevention, diagnosis treatment and care can help support people affected by the disease as well as their family and carers. The Policy Brief includes recommendations and targets key stakeholders in particular policy makers, health professionals and patients.

Eurohealth article: an article featuring MOPEAD was published in the December edition of Eurohealth (Volume 25, Issue 4) looking at "Enhancing the sustainability of long-term care". This article, '*Patient engagement strategies towards earlier diagnosis of Alzheimer's disease*' starts with the fact that AD is a challenging disease, diagnosed too late and with no treatment to cure the disease or alter its progressive course. In this article, MOPEAD is presented as an innovative way to tackle the underlying causes of late diagnosis or underdiagnosis through patient engagement of patients in the early diagnosis of AD. The article invites all stakeholders, people living with the disease, their carers, researchers and policymakers, to build upon the EU momentum to promote early intervention and implement supportive environments for the early diagnosis of AD.

Eurohealth is a publication of the European Observatory on Health and Policies.

MOPEAD Newsletter #3: this last project newsletter looks back at what the project has taught the participants and the community. The project's learnings, the data and knowledge generated are a legacy that will bring value to both scientific and policy communities, with the ultimate goal to support those impacted by AD in Europe. MOPEAD has opened new ways for citizens to be engaged with their brain and memory.

The newsletter also highlights how MOPEAD's communication strategy has greatly supported the participants during the course of the project. It includes an overview of the outcomes of the four patient engagement strategies that were tested and evaluated (Citizen Science, Open House (Memory Clinic), primary and tertiary care (diabetologists) settings). The project's key wins were discussions around the ethical issues linked to the project's innovative approach, insight into the cost-effectiveness of the different strategies, the survey among GPs to understand their attitude towards AD diagnosis, a gender policy brief that explores the biological and social factors with regard to sex and gender that impact the development, diagnosis, progression, treatment of AD, and the production of two documents 'Public education and awareness-raising strategies' and 'Recommendations for policy makers and regulators' that will serve to steer discussions on how to improve the diagnosis of AD.

During 2020, a number of articles will be published in peer review journals by project Consortium members who will present the results outcomes and findings.

MOPEAD Project Press Release

22 December 2019

About MOPEAD

MOPEAD is a 33-month project funded by the Innovative Medicines Initiative (IMI) that aims to deliver a step-change in Alzheimer's disease (AD) patient engagement strategies and a paradigm shift from late-stage diagnosis to early-stage diagnosis.

Four patient engagement strategies (citizens science, 'Open House' (memory clinic), primary and tertiary care) are being tested in five clinical sites in Germany, Slovenia, Spain, Sweden and the Netherlands. The strategies will be compared and contrasted to identify ways to improve the early detection and diagnosis of AD. The findings will enable models of patient access to be established and used in the broader AD community.

MOPEAD partners are Fundació ACE Institut Català de Neurociències Aplicades, Eli Lilly and Company Ltd, ASDM Consulting, AstraZeneca AB, European Institute of Women's Health, GMV Soluciones Globales Internet S.A.U., Karolinska Institutet, Modus Research and Innovation Ltd, Spomincica—Alzheimer Slovenia, University Hospital of Cologne, University Medical Centre Ljubljana, Fundacio Hospital Universitari Vall D'Hebron—Institut de Recerca, Stichting VUmc, Alzheimer Europe.

Why MOPEAD ?

MOPEAD will contribute to the imperative to find interventions to halt AD. Dementia affects over 35 million people globally, a figure set to rise to over 115 million by 2050 due to the ageing of the population. AD puts a huge and growing burden on health and social systems, and the families and carers of those affected. Despite decades of research, there is still no treatment nor cure for the disease. It is therefore crucial to develop new interventions that will help identify hidden cases of AD. MOPEAD will do this through evaluating four patient engagement strategies and providing new insights for therapeutic interventions in clearly identified populations.

MOPEAD will respond to the urgency of finding interventions to halt AD by stimulating a faster recruitment of patients into clinical trials.

www.mopead.eu
@MopeadEU

Disclaimer

This communication reflects the author's view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.

Notes to Editors

About Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently- needed new treatments in diverse areas.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented

MOPEAD Project Press Release

22 December 2019

by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

www.imi.europa.eu